Skip to main content
About
Executive Team
Board of Directors
How We Operate
Quality
Capabilities
Locations
News
Products
Contract Manufacturing
Investors
Careers
Careers
Benefits
Available Positions
Application
Contact
Contact Us
Locations
News
Overview
News
Events & Presentations
Stock Information
Stock Quote
Stock Chart
Investment Calculator
Analyst Coverage
Financials
Quarterly Results
Annual Reports
SEC Filings
Governance
Governance Documents
Executive Management
Board of Directors
Committee Composition
Resources
Investor FAQs
Information Request Form
Investor Email Alerts
Investor Contacts
Site Search
Normal
Press release year list
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2009
2008
11/22/2021
ANI Pharmaceuticals Completes Acquisition of Novitium Pharma, Significantly Enhancing R&D Capabilities and Scale of Generics and CDMO Businesses
11/22/2021
ANI Pharmaceuticals to Present at the Piper Sandler 33rd Annual Healthcare Conference 2021
11/11/2021
ANI Pharmaceuticals Receives Clearance from U.S. Federal Trade Commission for the Acquisition of Novitium Pharma
11/08/2021
ANI Pharmaceuticals, Inc. Announces Closing of $75 Million Public Offering of Common Stock
11/03/2021
ANI Pharmaceuticals, Inc. Announces Pricing of $75 Million Public Offering of Common Stock
11/03/2021
ANI Pharmaceuticals, Inc. Announces Proposed Public Offering of Common Stock
11/01/2021
ANI Pharmaceuticals Reports Third Quarter 2021 Results
11/01/2021
ANI Pharmaceuticals Announces FDA Approval of Purified Cortrophin™ Gel for Multiple Indications Including Multiple Sclerosis, Rheumatoid Arthritis and Nephrotic Syndrome
10/29/2021
ANI Pharmaceuticals to Discuss Third Quarter 2021 Financial Results on November 1, 2021
09/20/2021
ANI Pharmaceuticals to Present at Cantor Virtual Global Healthcare Conference 2021
09/17/2021
ANI Pharmaceuticals Announces Launch of Nebivolol Tablets
08/31/2021
ANI Pharmaceuticals Announces FDA Acceptance of Purified Cortrophin® Gel Supplemental New Drug Application for Multiple Indications Including Multiple Sclerosis, Rheumatoid Arthritis, and Nephrotic Syndrome
08/06/2021
ANI Pharmaceuticals Reports Second Quarter 2021 Results
07/22/2021
ANI Pharmaceuticals to Discuss Second Quarter 2021 Financial Results on August 6, 2021
07/06/2021
ANI Pharmaceuticals Announces Refiling of Cortrophin sNDA with FDA
06/15/2021
ANI Pharmaceuticals to Present at the Raymond James Human Health Innovation Conference 2021
06/01/2021
ANI Pharmaceuticals Announces Details of 2021 Virtual Annual Meeting of Stockholders
05/27/2021
ANI Pharmaceuticals to Present at Jefferies Virtual Healthcare Conference 2021
05/07/2021
ANI Pharmaceuticals Reports First Quarter 2021 Results
04/26/2021
ANI Pharmaceuticals to Discuss First Quarter 2021 Financial Results on May 7, 2021
04/06/2021
ANI Pharmaceuticals Expands Branded Products Portfolio Through Acquisition of Sandoz Inc. NDAs
03/09/2021
ANI Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Results; Company Positioned for Sustainable Future Growth
Download
PDF format download (opens in new window)
03/09/2021
ANI Pharmaceuticals to Acquire Novitium Pharma, Strengthening R&D Engine and Expanding Generics and CDMO Business
Download
PDF format download (opens in new window)
02/19/2021
ANI Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
02/17/2021
ANI Pharmaceuticals Strengthens Leadership Team to Accelerate Future Growth
02/16/2021
ANI Pharmaceuticals to Discuss Fourth Quarter and Full Year 2020 Financial Results on March 9, 2021
02/01/2021
ANI Pharmaceuticals Announces Launch of Prazosin Hydrochloride (“HCl”) Capsules